Home → Focus

Groundbreaking Rules for Electronic Health Records Proposed Print E-mail
Written by Vitale Health Law   
Monday, 18 February 2019 00:00
The U.S. Department of Health and Human Services is proposing new rules that could pave the way for increased exchange of healthcare data by 2020. The rules, issued by the Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC), would allow patients to have access to their electronic health records (EHR) at no charge. They also would be able to transfer them more easily from one provider to another. Instead of having patient information in disparate systems, the rules give all payers the ability to exchange data seamlessly and allow patients to obtain a complete picture of not only their own healthcare, but also their insurance claims information in one place. This would allow for better coordination of care.

Last Updated on Tuesday, 19 February 2019 17:37
Lab to Pay $63.5M to Settle Kickback Allegations Print E-mail
Written by Vitale Health Law   
Tuesday, 05 February 2019 18:19
Inform Diagnostics, an Irving, Texas-based pathology laboratory company, has agreed to pay $63.5 million to settle allegations that it violated the False Claims Act by  engaging in improper financial relationships with referring physicians. The settlement stems from allegations that the company violated the Anti-Kickback Statute and the Stark Lawby providing referring physicians with subsidies for electronic health records (EHR) systems and free or discounted technology consulting services. The Anti-Kickback Statute and the Stark Law restrict the financial relationships that health care providers, including laboratories, may have with doctors who refer patients to them.
Last Updated on Friday, 22 March 2019 17:54
Judge orders full release of redacted lawsuit against Purdue Pharma, maker of OxyContin Print E-mail
Written by Andrew Joseph | STAT   
Monday, 28 January 2019 00:00
A Massachusetts judge ruled on Monday that the state's lawsuit against Purdue Pharma for allegedly helping spawn the opioid crisis should be released in full to the public. Previous versions of the suit, which have already provided  new details about how the company marketed its blockbuster OxyContin painkiller, contained portions that were redacted. The complete document could shed light on decisions made by Purdue's board and how much money company executives made. The decision from Judge Janet Sanders in Suffolk County Superior Court came in response to a motion filed by media organizations, including STAT and the Boston Globe, to release the full lawsuit, which was originally filed by Massachusetts Attorney General Maura Healey in June.
Last Updated on Tuesday, 29 January 2019 17:57
How the shutdown is hitting healthcare Print E-mail
Written by Les Masterson | Healthcare Dive   
Friday, 25 January 2019 17:16
Hospital leaders, patient groups and others are speaking out about the potential of upheaval as the partial government shutdown moves into day 34. The shutdown is affecting healthcare in many ways, including stalled food inspections, people not being able to afford care and premiums and the possibility of Americans not receiving prompt tax credits that help pay their health insurance. Dozens of health groups sent a letter to President Donald Trump calling for the president and Congress to reopen government immediately to "minimize any further impact on the public's health and wellbeing."

Last Updated on Monday, 28 January 2019 18:18
Regulatory Dead Zone May Be Holding Up Copycat Insulin Print E-mail
Written by Andrew Dunn | Healthcare Dive   
Monday, 21 January 2019 00:00
The insulin market has increasingly attracted scrutiny from politicians, regulators and patient groups, as prices ramp higher for the hormone that millions of diabetics depend on to stay alive. Food and Drug Administration head Scott Gottlieb has advocated for greater competition in the pharmaceutical industry as a means of bringing down drug costs. But, for insulin, changing legal rules have effectively created a "regulatory dead zone," hindering generic drugmakers filing applications for copycat versions of the biologic drug. 

Last Updated on Tuesday, 22 January 2019 18:16
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 8 of 139

Website design, development, and hosting provided by